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Renin is the key physiologically regulated enzyme of the cascade that culminates in activation of the renin-Ang 
(angiotensin) system (RAS).1–14 Under normal physiological 
conditions, juxtaglomerular cells are the main, if not the only 
source of circulating, active renin, constituting, therefore, the 
endocrine branch of RAS.4,6,8 On reaching the circulation, renin 
generates Ang I by hydrolyzing its unique substrate angioten-
sinogen, which is an indispensable step for the subsequent for-
mation of Ang II.7,15,16 Thus, renin release by secretory cells 
in the juxtaglomerular apparatus (JGA) is the rate-limiting 
step in the activation of systemic RAS. Most RAS compo-
nents are present at the tissue level, and this system moreover 
is believed to be overactive in kidneys from rodent models and 
patients with diabetic kidney disease (DKD).17–26 By contrast, 
plasma renin activity (PRA) is usually low in patients with 
diabetic complications27–30 This is known as the renin-para-
dox.27,31,32 Despite the low/normal levels of circulating PRA, 
RAS blockers are effective in slowing down the progression of 
kidney disease.26,33–35 This beneficial effect reflects their direct 
suppressive actions of the kidney RAS which is in addition to 
their systemic effects.
The presence of renin was described in proximal and col-
lecting tubules as early as 1982.36 More recently, there has 
been an interest in urinary renin and its possible source, which 
could at least, in part, be of tubular origin.19,37–39 There is lim-
ited information on urinary renin in patients with diabetes mel-
litus and renal complications. It is possible that urinary renin, 
if increased, could contribute to activation of the RAS system, 
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Abstract—In patients with diabetic kidney disease (DKD), plasma renin activity is usually decreased, but there is limited 
information on urinary renin and its origin. Urinary renin was evaluated in samples from patients with longstanding type 
I diabetes mellitus and mice with streptozotocin-induced diabetes mellitus. Renin-reporter mouse model (Ren1d-Cre;mT/
mG) was made diabetic with streptozotocin to examine whether the distribution of cells of the renin lineage was altered 
in a chronic diabetic environment. Active renin was increased in urine samples from patients with DKD (n=36), compared 
with those without DKD (n=38; 3.2 versus 1.3 pg/mg creatinine; P<0.001). In mice with streptozotocin-induced diabetes 
mellitus, urine renin was also increased compared with nondiabetic controls. By immunohistochemistry, in mice with 
streptozotocin-induced diabetes mellitus, juxtaglomerular apparatus and proximal tubular renin staining were reduced, 
whereas collecting tubule staining, by contrast, was increased. To examine the role of filtration and tubular reabsorption on 
urinary renin, mice were either infused with either mouse or human recombinant renin and lysine (a blocker of proximal 
tubular protein reabsorption). Infusion of either form of renin together with lysine markedly increased urinary renin such 
that it was no longer different between nondiabetic and diabetic mice. Megalin mRNA was reduced in the kidney cortex of 
streptozotocin-treated mice (0.70±0.09 versus 1.01±0.04 in controls, P=0.01) consistent with impaired tubular reabsorption. 
In Ren1d-Cre;mT/mG with streptozotocin-induced diabetes mellitus, the distribution of renin lineage cells within the kidney 
was similar to nondiabetic renin-reporter mice. No evidence for migration of cells of renin linage to the collecting duct in 
diabetic mice could be found. Renin mRNA in microdissected collecting ducts from streptozotocin-treated mice, moreover, 
was not significantly different than in controls, whereas in kidney cortex, largely reflecting juxtaglomerular apparatus 
renin, it was significantly reduced. In conclusion, in urine from patients with type 1 diabetes mellitus and DKD and from 
mice with streptozotocin-induced diabetes mellitus, renin is elevated. This cannot be attributed to production from cells of 
the renin lineage migrating to the collecting duct in a chronic hyperglycemic environment. Rather, the elevated levels of 
urinary renin found in DKD are best attributed to altered glomerular filteration and impaired proximal tubular reabsorption.  
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a feature of diabetic and nondiabetic CKD. By cleaving angio-
tensinogen that is either filtered, locally formed, or both, renin 
could activate RAS locally within the kidney, which is rele-
vant to sodium retention, hypertension, glomerular hemody-
namics, inflammation and progression of CKD. We, therefore, 
reasoned that the source of urinary renin in DKD deserves fur-
ther investigation. We hypothesized that urinary renin in DKD 
is either the result of increased filtration because of alterations 
to the glomerular permeability or impaired proximal, tubular 
reabsorption, or both. We also wanted to examine the possi-
bility that urinary renin could be of tubular origin, that is lo-
cally produced by tubular segments, namely in the collecting 
ducts (CD). In this regard, it is important to note that the PRR 
(prorenin receptor), a dual receptor for renin and prorenin, is 
present in CD cells.19,40–43 Genetic ablation of the PRR in CD 
cells attenuates the hypertensive response to Ang II infusions 
suggesting that this receptor may act as a positive regulator of 
the intrarenal RAS.40,44 Augmented renin staining in the CD 
by Ang II and in streptozotocin-induced diabetes mellitus has 
been reported.19,36,45 In rats with Ang II–dependent hyperten-
sion with marked suppression of PRA, urinary levels of renin 
were increased which was taken as evidence of possible se-
cretion by CD cells into the luminal fluid.7 Renin mRNA can 
be detected not only in the proximal tubules (PT) but also in 
the CDs.4,45 The finding that renin mRNA can be detected in 
renal medulla, which is devoid of JGA, would be consistent 
with the notion that renin secreted in CDs could be a source of 
urinary renin.45 These findings, moreover, could be interpreted 
to suggest that renin originating from tubular sites can foster 
kidney RAS activation.19,45 In this scenario, increased tubular 
renin could be reflected by increased urinary renin and be used 
as a potential marker of increased kidney RAS activity. This 
would be of interest particularly in the context of DKD where 
levels of PRA are usually low.27,28
The objective of the present study was, therefore, to ex-
amine the origin of urinary renin both in patients with type 1 
diabetes mellitus with or without DKD and in mice with strep-
tozotocin-induced diabetes mellitus. The role of proximal tu-
bular reabsorption and tubular formation of renin as a potential 
source of urinary renin were explored in the setting of DKD by 
infusing recombinant renin when proximal tubular reabsorp-
tion was blocked by l-lysine. Finally, we used a renin-reporter 
mouse model (Ren1d-Cre;mT/mG) made diabetic using strep-
tozotocin to examine whether the distribution of cells of the 
renin lineage was altered in a chronic diabetic environment.
Methods
The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Study Cohort
People with type 1 diabetes mellitus, who were seen in the Diabetes 
Care Center (University of Washington) for outpatient endocrinology 
care, were approached for participation in the Kidney Research Institute 
Diabetic Kidney Disease Repository (University of Washington) and 
were enrolled into the repository after providing informed consent. 
Demographic and clinical information was obtained from the elec-
tronic medical records and a questionnaire completed by the partici-
pants. DKD was defined as either a urine albumin-to-creatine ratio 
(ACR) ≥300 mg/g or an estimated glomerular filtration rate (GFR) 
<60 mL/(min·1.73 m2) and ACR ≥30 mg/g. People with longstanding 
diabetes mellitus but no evidence of overt DKD were those with ≥25 
years of type 1 diabetes mellitus, estimated GFR ≥90 mL/(min·1.73 
m2), and ACR <30 mg/g. Demographic and clinical data (age, race, sex, 
diabetes mellitus duration, and RAS inhibitor use) were obtained from 
the electronic medical records and confirmed by patient questionnaires 
(race, diabetes mellitus duration and RAS inhibitor use). Diabetes mel-
litus type was extracted from the clinical notes, as ascertained by the 
endocrinologists caring for the patients. Hemoglobin A1c and serum 
creatinine were obtained from the electronic medical records at a time 
closest to the date of urine sample collection. GFR was calculated from 
the serum creatinine using the Chronic Kidney Disease Epidemiology 
Collaboration formula. A random clean-catch, mid-stream urine sample 
was collected and stored at 4oC after collection, until processed The use 
of human samples, and data were approved by the Institutional Review 
Board of the University of Washington. Urine samples used for this 
study were centrifuged at 4700g for 15 minutes at 4°C, and the super-
natant was collected, aliquoted, and stored at −80°C. The mean (SD) 
time from sample collection to storage at −80°C was 5.7 (2.0) hours.
Laboratory Measurements in Human Urine 
Samples
Albumin and creatinine were measured using an immunoturbi-
dometric assay and the modified rate Jaffe reaction, respectively, 
using a DXC 600 clinical chemistry analyzer (Beckman Coulter, 
Indianapolis). Active renin was measured using a quantitative solid-
phase sandwich ELISA distributed by DRG Instruments (Marburg, 
Germany) with a minimum detection limit of 0.8 pg/mL and 0.69% 
crossreactivity with prorenin. Before active renin measurements, 
each sample was individually concentrated (6×) using Spin-X 5 kD 
devices. The coefficients of intra and interassay variation for active 
renin ELISA in human urine samples were 4.9% and 12.7%, respec-
tively. Internal controls were included (one for high renin and one for 
low renin values) to assure consistency of interassay performance. In 
addition, ELISA data for urine active renin were compared with those 
reported in the literature. The geometric mean (range) in our study for 
all tested urines with detectable active renin were 1.64 (0.14–17.2) 
pg/mL (n=65). This was in keeping with the geometric mean and 
range reported in the literature (1.46 (0.13–157) pg/mL using a com-
pletely different approach (enzyme-kinetic assay) in 43 urines from 
mainly type 2 diabetic subjects.46
In addition, total renin was measured using a quantitative solid-
phase sandwich ELISA distributed by R&D Systems (Minneapolis, 
MN) with a sensitivity of 14.8 pg/mL. According to the manufacturer, 
this assay recognizes both human recombinant prorenin and renin. 
The kit for total human renin was tested by the manufacturer specifi-
cally for human urine samples.
We also attempted to measure urinary prorenin using a quantitative 
solid-phase sandwich ELISA distributed by Molecular Innovations 
(Novi, MI) with a minimum detection limit of 0.016 ng/mL. This as-
say was reported by the manufacturer to be specific for prorenin only 
with no detectable crossreactivity with human, mouse, and rat renin. 
However, because of poor reproducibility of prorenin measurements 
in our samples (Interassay coefficient of variation=69.5%, n=47), we 
do not present the data obtained with human prorenin assay as we had 
to deem the results as questionable.
Experimental Animals
Female Friend Virus B NIH Jackson mice were acquired from 
Jackson Laboratories (Bar Harbor, ME).
The Ren1d-Cre; mT/mG is a double transgenic reporter mouse 
model expressing Cre recombinase from the endogenous renin locus 
(Ren1D) and the mT/mG cassette from the Rosa26 locus.10 The 2 re-
porter genes, membrane-targeted fluorescent tomato protein (mT, red) 
and membrane-directed eGFP (enhanced green fluorescent protein; 
mG) were used to trace renin lineage cells (RLCs) in kidneys of diabe-
tic and control mice. Whereas mT is expressed before recombination, 
mG is only expressed in cells post–Cre-expression and recombina-
tion. Thus, because gene expression from the Rosa26 locus is ubiqui-
tous and gene switch is stably transferred to cell progeny, only RLCs 
are green (mG positive), whereas all non-RLCs remain mT positive. 
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Animals were housed at the Center for Comparative Medicine 
at Northwestern University Feinberg School of Medicine. Animal 
care and procedures were approved by the Institutional Animal Care 
and Use Committee at Northwestern University and in accordance 
with the National Institutes of Health Guide for the Care and Use 
of Laboratory Animals and the institutional, state, and federal guide-
lines. The total number of animals enrolled was 126.
Diabetes Mellitus Induction Using Streptozotocin
Streptozotocin (150 mg/kg, Sigma Chemical, St Louis, MO) dissolved 
in sodium citrate buffer pH 4.5 (streptozotocin-treated mice) or sodium 
citrate buffer pH 4.5 alone (nondiabetic vehicle controls) was injected 
in 2 intraperitoneal injections to female FVB mice at 19 to 20 weeks 
of age. Spot urines were collected 8 and 20 weeks after the last strep-
tozotocin or vehicle injection (at 28 and 40 weeks of age, respectively) 
and stored at −80oC. Human recombinant renin (hrRenin, Molecular 
Innovations, Novi, MI) was administered as a single intravenous bolus 
injection to female FVB/N mice at the dose of 0.5 µg/g body weight. 
To determine the impact of renin reabsorption in the proximal tubule, 
lysine, a blocker of proximal tubular reabsorption,48 was administered 
(0.4 mg/g body weight) as a single combination injection together 
with hrRenin and as a single injection without hrRenin. Urine was 
collected immediately before (baseline) and within 3 hours after in-
jection. The timeline of the experiment was as follows: mice were 
weighted; then baseline urines were collected; within 5 to 10 minutes 
after voiding, mice were administered with lysine, hrRenin, or both 
in a single intravenous injection (0.2 mL/mouse); immediately after 
intravenous injection to collect urine, mice were placed for 3 hours in 
urine collection cages with access to water and food.
Laboratory Measurements in Mouse Samples
Ang I and Ang II were extracted and measured by Liquid 
Chromatography - Tandem Mass Spectrometry as previously 
described.49 Active human renin was measured using a quantita-
tive solid-phase sandwich ELISA distributed by DRG Instruments 
(Marburg, Germany). Mouse total renin was measured using a quan-
titative solid-phase sandwich ELISA distributed by RayBiotech 
(Norcross, GA) with a minimum detection limit of 6 pg/mL. Albumin 
was measured by a quantitative solid-phase sandwich ELISA (Albuwell 
M, Exocell, Philadelphia, PA). Creatinine was measured using the Jaffe 
method (Creatinine Companion, Exocell, Philadelphia, PA).
Western Blot of Mouse Urine Samples
For Western blot of urines, proteins were separated by SDS-PAGE 
and transferred to polyvinylidene difluoride (PVDF) membranes. 
The membranes were blocked in nonfat dry milk solubilized in Tris-
buffered saline solution, pH 8.0 containing 0.1 %Tween 20 (7% wt/
vol). The PDVF membranes were incubated with primary anti-Renin/
Prorenin antibody (Molecular Innovations) and horseradish peroxi-
dase–conjugated secondary antibody (Santa Cruz Biotechnology). 
Bands were visualized using chemiluminescence system (Super 
Signal Pico, Pierce). For comparisons of urinary renin bands between 
control and lysine-injected groups, several gels were used in which 
a similar number of samples from each group was included. The av-
erage value of integrated density measured in controls was set as 
100% for each gel, and the results for injected mice were expressed 
as percentage of that measured in controls.
Immunohistochemistry
Paraffin blocks were cut at 4 μm and deparaffinized in xylene and 
rehydrated through graded alcohols. Antigen retrieval was performed 
with a pressure cooker at 120°C in target retrieval solution (DAKO). 
Endogenous peroxidase activity was blocked with 3% hydrogen per-
oxide. Slides were incubated overnight at 4°C with rabbit anti-mouse 
renin polyclonal antibody (1:500), washed, and incubated with sec-
ondary antibody conjugated with peroxidase-labeled polymer (DAKO). 
After incubation with 3,3′-diaminobenzidine chromogen, slides were 
counterstained with hematoxylin. Sections were dehydrated and cov-
ered with Permount (Fisher Scientific). Coverslips were viewed using a 
Zeiss microscope. To evaluate renin protein expression in kidneys from 
streptozotocin-treated and vehicle control mice (n=9 in each group), 
a semiquantitative analysis of the immunoperoxidase-stained sections 
was performed. Two masked observers performed evaluation of renin 
staining within JGA, CD, and PT. The percentage of JGAs with visible 
renin staining, the number of renin stained collecting tubules, and the 
intensity of PT staining in the viewing areas (5 viewing fields per slide) 
were evaluated. The percentage of renin-positive JGA (JGA index) was 
calculated as (the number of renin-positive JGA in all sections)×100/
(the total number of glomeruli observed).50 Every section was exam-
ined observer-blinded using the same magnification (×200), and only 
the JGA with a classic donut-shaped outline was evaluated.
Immunofluorescence
Cryosections (7 μm) were cut using a cryostat from the frozen blocks 
of Ren1d-Cre; mT/mG mouse kidneys and subsequently subjected 
to the immunostaining for AQP2 (aquaporin 2; 1:200; Santa Cruz 
Biotechnology) and renin. Kidney sections from Ren1d-Cre;mT/mG 
mice were screened for the presence of GFP+ in CD epithelial cells 
based on colocalization with AQP2 immunostaining in both diabetic and 
nondiabetic animals using Fiji software (National Institutes of Health). 
A Pearson correlation coefficient was used to quantify the colocaliza-
tion parameters. Moreover, a large image analysis of the GFP and AQP2 
colocalized area per total area was performed to assess any differences 
between kidneys of control and diabetic Ren1d-Cre;mT/mG mice.
In addition, kidney sections were assessed for the presence of 
GFP+ cells in control and diabetic Ren1d-Cre;mT/mG mice within 
the parietal glomeruli and glomerular tuft and quantified as percent-
age of glomerular GFP positivity.
Microdissection of Renal Tubule Segments
Streptozotocin-treated mice and vehicle controls were euthanized by 
an overdose of Euthasol (390 mg pentobarbital-Na and 50 mg phe-
nytoin-Na per mL).
Both kidneys were rapidly removed and transferred into ice-cold 
HEPES solution. After removal of the capsula and pelvis, the kidneys 
were cut into 1- to 2-mm thick coronal slices. Usually, 3 or 4 slices 
from the middle of each kidney could be obtained due to the thickness 
of the cortex and medulla. For the preparation of the tubules, 1- to 
2-mm slices of the respective region were prepared under a stereo 
microscope and transferred into the prewarmed digestion solution. 
Cortical and outer medullary tissue was then incubated in a diges-
tion solution containing 4 mL MEM (GibcoBRL), 5 mmol/L glycine, 
6 mg/mL trypsin inhibitor type II-S (Sigma T-9128), and 250 g/mL 
collagenase (Sigma C-9891), pH 7.4 at 37ºC in a water bath for 25 
minutes without shaking. When the medium became cloudy on gen-
tle shaking, the digestion was stopped by transferring the tubules to 
ice, carefully removing the supernatant and replacing it with 4 mL 
ice-cold 1% BSA-HEPES solution. The BSA-HEPES solution was 
replaced with ice-cold HEPES solution after 10 minutes and tubules 
were maintained on ice until use. Isolated tubules were selected at 
4ºC under a stereo microscope after 0.5 mL of the tubule suspension 
had been diluted in 10 mL of ice-cold HEPES solution. Individual 
tubule segments were identified by their appearance and topology. 
For the proximal tubule segments, S1 was identified as the proximal 
tubule directly attached to the glomerulus, S2 was the straight part in 
the medullary ray, and S3 was the proximal tubule in the outer me-
dulla. The cortical CD (CCD) was dissected from the medullary rays 
of the cortex. Around 100 proximal tubule segments and 30 CCD 
segments were dissected from each mouse kidney.
Reverse Transcription–Polymerase Chain Reaction 
Analysis
Total RNA from kidney cortex tissue was obtained by using Trizol rea-
gent (Thermo Fischer Scientific, Waltham, MA). Constant amounts of 
1 µg of extracted kidney cortex RNA, as well as the totality of the total 
RNA obtained from microdissected tubules (using Arcturus PicoPure 
RNA kit from Applied Biosystems), were reverse transcribed to syn-
thesize cDNA. Synthesis of cDNA was performed using Reverse 
Transcription Kit on a GenAmp PCR System 9700 (both Thermo 
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Quantitative polymerase chain reaction was run on a 96-well plate 
using a Step One Plus PCR System (Thermo Fischer Scientific, 
Waltham, MA). GAPDH was used as an internal control for normal-
ization. Each reaction was performed in duplicates. Sequences of the 
primers for quantitative polymerase chain reaction (IDT, Coralville, 
IA) are shown in Table S1 in the online-only Data Supplement.
Statistical Analysis
Shapiro-Wilk was used to test normality. Normally distributed data 
are reported as the arithmetic mean±SEM. Distribution of nonnor-
mally distributed data was described using median and interquartile 
range. Differences between 2 groups with normal distribution were 
analyzed using a 2-tailed Student t test and for nonnormally distrib-
uted data (eg, urinary ACR), using nonparametric Mann-Whitney 
test. To assess correlation between variables, Spearman correlation 
coefficient was used for nonnormally distributed data and Pearson 
correlation coefficient for normally distributed data. Fisher exact test 
was used in the analysis of contingency tables. Interaction between 2 
independent variables was assessed using 2-way ANOVA. The nom-
inal significance threshold was set as a 2-sided P<0.05. The IBM 
SPSS software (version 23) and GraphPad Prism software (version 8) 
were used for the statistical analyses.
Results
Studies in Urine Samples From Patients With Type 
1 Diabetes Mellitus
Characteristics of the Cohort of Patients With Type 1  
Diabetes Mellitus
Urine samples were obtained from a carefully characterized co-
hort of patients with type 1 diabetes mellitus at the University 
of Washington, Seattle. The majority of patients were white 
in both groups. There were no significant differences in age 
and sex distribution between patients with and without DKD, 
which both had male predominance (Table S2). Hemoglobin 
A1c was significantly higher in the DKD than in the non-DKD 
group (median 8.3 versus 7.5%; P=0.002). Both groups had 
prolonged disease duration of diabetes mellitus, but it was 
slightly but significantly longer in the group without DKD than 
in the group with DKD (median 32 versus 37 years, P=0.032). 
Therefore, the group without DKD had very low risk of devel-
oping it after such a long period of disease duration.51
As expected from the selection criteria, the group without 
DKD had urinary albumin excretion in the normal range and an 
estimated GFR above 90 mL/(min·1.73 m2), whereas the group 
with DKD had urinary albumin excretion either in the micro 
or macroalbuminuric range and an estimated GFR below 60 
mL/(min·1.73 m2). The median estimated GFR was lower (me-
dian 39 versus 101 mL/[min·1.73 m2]; P<0.001), whereas ACR 
was higher (median 497 versus 7 mg/g creatinine; P<0.001) in 
people with DKD, compared with those without DKD (Table 
S2). RAS-blocker use was more prevalent in people with DKD 
than in those without (86 versus 50%; P=0.001).
Urine Renin and Albumin in Patients 
With and Without DKD
Active urinary renin was detectable in 94% (34/36) of urines 
from the cases and 82% (31/38) of urines from controls with 
no DKD. Total urinary renin was detectable in 56% (20/36) of 
samples from the cases but only in 9% (5/35) of the urines from 
the controls with diabetes mellitus but no DKD. For subsequent 
analyses, the values below the lower limit of quantification of 
the assays were set to 0.5×lower limit of quantification. Median 
creatinine-normalized urine active renin concentrations were 
significantly higher in people with DKD as compared to those 
without DKD (3.2; 2.1, 9.5 versus 1.3; 0.5, 2.8 pg/mg creatinine; 
P<0.001; Figure 1A). The urinary albumin/creatinine ratio was 
markedly higher (by study design) in the group with CKD than 
in the group without (Figure 1B). A significant positive correla-
tion between active renin and ACR was found (Spearman coef-
ficient: r=0.454, P=0.000062, 95% CI, 0.2420–0.6247).
Median creatinine-normalized urine total renin concentra-
tions were also significantly higher in people with DKD than 
in people without DKD (P=0.023; Figure S1). A positive cor-
relation between creatinine-normalized total urine renin and 
creatinine-normalized urine albumin was found (Spearman 
coefficient: r=0.410, P=0.0005, 95% CI, 0.1851–0.5941).
Urinary Mouse and Plasma Renin in Experimental 
DKD Caused by Streptozotocin in Mice
At 8 weeks post-streptozotocin injections, a significant increase 
in urinary renin normalized for creatinine was found in mice 
treated with streptozotocin (n=15) compared with those treated 
with vehicle (n=8; 455±106 versus 113±27 pg/mg creatinine; 
P=0.005) (Figure 2A). Albumin was significantly increased 
in mice injected with streptozotocin compared with controls 
(69±23 versus 11±3 µg/mg creatinine; P=0.006) as was the 
blood glucose (549±15 versus 157±6 mg/dL; P<0.01). Twenty 
weeks after streptozotocin administration, hyperglycemia and 
albuminuria also developed, and the data on these parameters 
have been previously reported.23 Here, we show urinary data 
from the same animals, not previously reported. Urinary total 
mouse renin/creatinine ratio was significantly higher in mice 
treated with streptozotocin (1093±319 pg/mg creatinine, n=15) 
as compared to those treated with vehicle (64±19 pg/mg cre-
atinine, n=8, P=0.0001; Figure 2B). A significant positive cor-
relation was found between total renin and albumin both at 8 
(Spearman coefficient: r=0.477, P=0.018, 95% CI, 0.07867 
to 0.7441) and 20 poststreptozotocin injection (Spearman 
Figure 1. Active renin/creatinine (Cr) ratio and 
albumin/Cr ratio in patients with and without 
diabetic kidney disease (DKD) in longstanding type 1 
diabetes mellitus. People with no DKD had estimated 
glomerular filtration rate (eGFR) ≥90 mL(min·1.73 
m2) and albumin-to-Cr ratio (ACR) <30 mg/g after 
≥25 y of type 1 diabetes mellitus. Those with DKD 
had either an ACR ≥300 mg/g or both eGFR <60 
mL(min·1.73 m2) and ACR ≥30 mg/g. A, higher active 
renin/Cr ratio in urines from patients with DKD (black, 
n=36) compared with those without DKD (white, 
n=38). B, Higher albumin/Cr ratio in urines from 
patients with DKD (black, n=34) compared with those 
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coefficient: r=0.704, P=0.0002, 95% CI 0.4006–0.8685), re-
spectively. When the 2 age groups were combined, a signifi-
cant positive correlation was also found Spearman coefficient: 
r=0.628, P=0.0000023, confidence interval 0.4089–0.7790).
Because we did not have enough plasma volume for PRA 
measurements, we assessed indirectly using an approach re-
cently described by Domenig et al.52 In this approach, the 
summation of Ang I and Ang II serves as a strong surrogate 
for PRA.52 We applied this concept to our studies and thus 
inferred PRA from the sum of Ang I and Ang II measured 
by LC-MS/MS in streptozotocin-treated and control mice. 
The inferred PRA from the sum of plasma Ang I and Ang 
II was lower in streptozotocin injected mice than in the con-
trol group, but the difference was not statistically significant 
(83±52 versus 267±179 pg/mL; P=0.230).
Effect of l-lysine Infusions on Urinary Renin
The effect of lysine on total urinary renin excretion was first 
evaluated in a separate set of control mice using Western blots. 
A renin immunoreactive protein band appeared at around 37 
kDa in urines from mice injected with l-lysine (n=6), which 
was barely detectable in urines of noninjected control mice 
(n=7; Figure S2A). Densitometric analysis showed that the rel-
ative abundance of the renin immunoreactive protein band at 37 
kDa was significantly increased in urines from mice injected 
with lysine compared with urines from noninjected controls 
(1912±890 % of control FVB mice, P=0.001; Figure S2B).
Having shown the increase in renin protein by Western blot, 
we next used ELISA. Urinary creatinine-normalized renin was 
>100-fold increased in mice injected with lysine (n=7) com-
pared with noninjected controls (n=8; 8950±2337 versus 64±19 
pg/mg creatinine; P=0.001; Figure 3A). This data shows that ly-
sine, by blocking proximal tubular reabsorption of endogenous 
renin, results in a large increase of urinary renin.
In diabetic mice, urinary renin/creatinine ratio in mice 
injected with lysine (n=8) was about 10-fold increased as 
compared to noninjected mice (n=15; 11 372±4126 versus 
1093±319 pg/mg creatinine; P<0.001, Figure 3A). Although 
the levels of renin were higher in diabetic mice than in con-
trols, the relative renin/creatinine increase after lysine injec-
tion is actually greater in control mice than in diabetic mice. 
This suggests a preexisting defect of proximal tubular reab-
sorption in diabetic mice. In noninjected mice, urinary renin/
creatinine ratio is significantly increased in diabetic mice 
compared with control mice (1093±319 versus 64±19 pg/
mg creatinine; P<0.001), whereas in lysine-injected mice, 
the increase of renin/creatinine ratio in diabetic mice com-
pared with control mice no longer is significantly different 
(11 372±4126 versus 8950±2337 pg/mg creatinine; P=0.908, 
Figure 3A). Moreover, the effect of lysine administration was 
not significantly different between streptozotocin-treated and 
control mice when analyzing the interaction between lysine 
and diabetes mellitus status by 2-way ANOVA (P=0.4).
Figure 2. Mouse renin concentrations in nondiabetic 
and diabetic mice, 8 (A) and 20 wk after the last 
streptozotocin (STZ) injection (B). A, higher mouse 
renin/creatinine (Cr) ratio in urines from diabetic FVB 
mice (STZ, black, n=15) compared with nondiabetic 
FVB mice (Veh, white, n=9) 8 wk after the last 
injection of steptozotocin. B, Higher mouse renin/Cr 
ratio in urines of diabetic FVB mice (STZ, black, n=15) 
compared with nondiabetic FVB mice (Veh, white, 
n=8) 20 wk after the last injection of STZ. Data shown 
as mean±SE. STZ denotes streptozotocin-treated 
mice. Veh indicates control mice treated with vehicle; 
**P<0.01, ***P<0.001.
Figure 3. A, Effect of lysine on urinary mouse renin in control and diabetic mice (B). Human active renin/creatinine (Cr) in nondiabetic and diabetic mice 
infused with human recombinant renin (hrRenin) and lysine. A, Mouse renin/Cr ratio in urines from control (white) and diabetic (black). Mice were infused with 
lysine (Lysine [circles]; control n=7, diabetic n=8) or did not receive lysine infusion (no infusion [squares]; control n=8, diabetic n=15). In noninfused animals, 
total renin was higher in streptozotocin (STZ)-treated compared with controls, whereas after lysine infusion no significant differences existed between the 2 
groups. Data shown as mean±SE. ***P<0.001. B, In mice infused with both hrRenin and lysine, urinary human active renin/Cr is markedly elevated, but there 
is no significant difference in STZ treated (closed symbols) vs nondiabetic mice (control, open symbols). Human active renin is undetectable in urines from 
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Urinary Human Active Renin Concentrations After 
Human Recombinant Renin and Lysine Infusions 
to Normal Mice and Streptozotocin-Treated Mice
hrRenin was injected to control and streptozotocin-treated 
mice to examine the renal handling of exogenous renin, dis-
tinct from mouse renin. In this model, the renin recovered in 
the urine provides an estimate of the renal handling of exog-
enous renin. As expected, human active renin was not detect-
able in urine samples from noninfused mice and mice infused 
with lysine only. This shows that the ELISA for human active 
renin does not recognize mouse renin. Urines of control mice 
injected with hrRenin (n=12) showed substantial levels of 
creatinine-normalized human active renin as compared to 
noninfused control mice in which it was not detectable (n=17; 
30±11 versus 0±0 pg/mg creatinine; P<0.001). This demon-
strates that human renin can be filtered but does not reveal 
the extent of how much is reabsorbed. In diabetic mice, in-
jection of hrRenin (n=10) also resulted in an increase in uri-
nary creatinine-normalized-human active renin as compared 
to noninjected diabetic mice (n=15; 779±625 versus 0±0 pg/
mg creatinine; P<0.001).
The difference in urinary hrRenin between control and 
diabetic mice after infusion of hrRenin was large (779±625 
versus 30±11 pg/mg creatinine, P=0.032). This reflects either 
increased filtration, impaired tubular reabsorption or both in 
diabetic mice.To estimate the effect of tubular reabsorption 
on urinary renin, lysine was infused together with hrRenin. 
Urines of control mice injected with a combination of lysine 
and hrRenin (n=7) had markedly higher urinary creatinine-
normalized hrRenin than those of control mice infused with 
hrRenin only (n=12; 1720±1151 versus 30±11 pg/mg creati-
nine, P=0.001). In the streptozotocin-treated group, combined 
injection of lysine and hrRenin (n=9) also resulted in an in-
crease of urinary human active renin compared with injection 
with hrRenin only (n=10), but it did not reach statistical signif-
icance (2418±994 versus 779±625 pg/mg creatinine, P=0.05). 
There was no apparent interaction between injection of lysine 
and diabetic status when analyzed by 2-way ANOVA (P=0.3).
In the streptozotocin-treated group infused with a combi-
nation of hrRenin and lysine, urinary human active renin was 
not significantly different than in controls infused with a com-
bination of hrRenin and lysine (2318±994 versus 1720±1151 
pg/mg creatinine, P=0.368, Figure 3B). Thus, in the presence 
of lysine induced blockade of proximal tubule reabsorption, 
the amount of infused human renin that appears in the urine is 
about the same in diabetic mice as in controls. This suggests 
the preexistence of a defect in proximal tubular reabsorption 
of renin in diabetic mice.
Kidney Renin Immunostaining in 
Streptozotocin-Treated Mice
Immunohistochemistry was used to examine renin protein 
expression in the kidney from control and streptozotocin-
treated mice. By immunohistochemistry, the main sites of 
staining were the JGA and kidney collecting tubules. Control 
animals had strong JGA staining and weak renin staining in 
collecting tubules. In contrast, in kidneys from streptozotocin-
treated animals, JGA staining was reduced, whereas collect-
ing tubule (CD) staining was increased (Figure 4A and 4B). 
The differences in JGA and CD staining between control 
and streptozotocin-treated mice was statistically significant 
(P<0.01) based on observations performed by 2 blinded inde-
pendent observers. Renin staining was also observed along the 
brush border of PT, but it seemed to be much weaker than in 
JGA and in CD. Based on observations performed by 2 blinded 
independent observers, PT renin staining in diabetic mice was 
significantly less abundant than in control mice (0.59±0.08 
versus 1.09±0.09 average intensity of renin stained PT/area; 
P=0.0012; Figure 4C).
Kidney Renin mRNA Expression in Kidney 
Cortex and Microdissected Tubules
Renin/GAPDH mRNA in the kidney cortex, which is largely 
representative of juxtaglomerular mRNA levels, was signifi-
cantly lower in diabetic (n=12) as compared to control mice 
(n=11; 0.78±0.1 versus 1.39±0.3, P = 0.04, Table S3). We 
next investigated whether the decreased renin staining in the 
PT and increased renin staining in the CD of diabetic mouse 
kidneys could be a result of different levels of renin mRNA 
expression in the respective areas. For this, we used micro-
dissected kidney PT and CCDs from control and diabetic 
mice. No significant differences were observed in the levels of 
mouse renin mRNA in either the PT or in the CCD (Table S3).
Kidney Megalin and Mannose-6-Phosphate 
Receptor mRNA in Experimental DKD
To evaluate receptors that are involved in the reabsorption of 
renin in the proximal tubule, the mRNA of megalin and M6PR 
(mannose-6-phosphate receptor) was evaluated. Both recep-
tors are present in the proximal tubule and bind renin and other 
proteins.53 Reverse transcriptase real-time polymerase chain 
reaction was used to measure megalin and M6PR expression 
in kidney cortex from control and streptozotocin-treated mice. 
Mouse megalin mRNA in diabetic mice was detected at a sig-
nificantly lower level than in control mice in kidney cortex 
(ratio megalin/GAPDH mRNA, 0.70±0.09 versus 1.01±0.04, 
P=0.01, n=6; Figure S3A). The levels of M6PR mRNA in di-
abetic mice, however, were not different from control mice in 
kidney cortex (ratio M6PR/GAPDH mRNA, 1.03±0.06 versus 
0.97±0.07, P=0.573, n=6; Figure S3B).
Ren1d-Cre;mT/mG With Streptozotocin-
Induced Diabetes Mellitus
A double transgenic mouse model was used to trace RLC in 
control and diabetic kidneys.6 The mT/mG construct switches 
from membrane-directed fluorescent tomato protein (mT, 
red) to membrane-directed eGFP (mG) expression after 
Cre-mediated recombination. Therefore, all RLCs are mG 
positive, whereas all non-RLCs remain mT positive.6 Ren1d-
Cre;mT/mG was made diabetic using streptozotocin, and the 
animals were studied 11 to 12 weeks after the last streptozoto-
cin injection.
To examine the RLCs in the CD, immunostaining for AQP2 
was used as a marker of principal cells. Using confocal laser 
scanning microscopy, we analyzed the overlay of mG positive 
RLCs and AQP2 positive CD cells. Colocalization was quan-
tified using Fiji software. We found no significant differences 
in colocalization at CD sites between kidneys from diabetic 
(n=5) and control mice (n=5; Pearson correlation coefficient: 
0.34±0.04 versus 0.31±0.04; P=0.632; Figure 5). This find-
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immunohistochemistry (see Figure 4) cannot be attributed to 
the migration of RLCs to the CD in diabetic mouse kidneys.
We next evaluated the RLCs in the glomeruli of diabetic 
and nondiabetic renin-reporter mice. In both, mG positive cells 
were found within the Bowman capsule of the glomerulus and 
to a lesser extent in the intraglomerular compartment namely, 
mesangial cells (see examples in Figure S4A). The quantita-
tion of the frequency mG positive cells revealed that in the 
parietal epithelium of the glomeruli RLC cells were observed 
in about 40% of the time, whereas within the intraglomerular 
mesangium, they were found in only 5% to 10% of the time 
(Figure S4B). Comparing control and streptozotocin-treated 
mice in regards to mG positive cells, no significant differences 
were found in either parietal or intraglomerular staining be-
tween both groups (Figure S4B).
Finally, renin protein staining was performed in renin-
reporter mice to find out which of the RLCs are associated 
with renin protein. Positive colocalization of renin with RLC 
near the vascular pole of the glomerulus was found, reflecting 
the physiological site of renin secretion (Figure 6A). By con-
trast, only few tubular epithelial structures had a colocaliza-
tion of renin and RLC (Figure 6B).
Discussion
This report shows that in people with type 1 diabetes mel-
litus who have developed DKD, urinary renin is increased as 
compared to a group who had not developed it after similar 
disease duration (≥25 years of diagnosis of diabetes mellitus). 
Consistent with the findings in humans with DKD, urinary 
renin was also markedly increased in streptozotocin-treated 
diabetic mice, a model of early DKD. The concordant increase 
in urinary renin in an experimental model of diabetes mellitus 
and in human DKD associated with type 1 diabetes mellitus is 
in agreement with previous studies where key components of 
the RAS system including renin were similarly altered.23,46,54
Renin-producing cells in adult life are restricted to the JGA 
localization, whereas in fetal life these cells are also found in 
large intrarenal arteries, inside the glomeruli, and in the inter-
stitium.6 As maturation continues, the number of renin-produc-
ing cells is reduced as they differentiate into arteriolar smooth 
muscle and mesangial cells and become progressively restricted 
to the JGA localization.5,6In response to a threat to homeostasis, 
requiring more renin, smooth muscle cells, and mesangial cells 
may acquire the renin phenotype and synthesize renin again until 
the crisis passes.5,6 For instance, agents that inhibit the response 
Figure 4. Kidney renin immunostaining in nondiabetic and diabetic FVB mice and semiquantitative analysis of staining in the juxtaglomerular apparatus (JGA; 
A), cortical collecting duct (CCD; B) and proximal tubule (PT; C). A, Immunostaining for renin shows a significant decrease of the percentage of glomeruli 
with stained JGA (black arrows) in diabetic FVB kidneys (streptozotocin [STZ]) compared with nondiabetic FVB kidneys (control). B, Immunostaining for renin 
shows a significant increase in the average number of stained CCD per area (black tip) in kidneys of diabetic FVB mice compared to nondiabetic FVB mice. 
C, Immunostaining for renin shows a significant decrease in the average intensity of stained PT per area (yellow arrow) in diabetic FVB kidneys compared 
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to Ang II (such as the ACE [angiotensin-converting enzyme] in-
hibitor captopril) result in an increase in the number of JGA cells 
that express renin and an accompanying increase in the number 
(recruitment) of renin-expressing cells along the afferent arte-
riole and sometimes in the glomerulus.9 By contrast, ureteral 
reflux leads to recruitment of renin-expressing mesangial cells 
and tubular cells.55 Despite its importance as the most frequent 
cause of CKD, the impact of diabetes mellitus on RLC has not 
been previously studied. To ascertain whether there is an increase 
in RLC along the nephron and particularly in the CD that could 
Figure 5. Renin lineage and aquaporin 2 
expressing cells in nondiabetic and diabetic 
Ren1d-Cre;mT/mG mouse kidneys (A) and 
colocalization analysis (B, C). A, Kidney 
sections from Ren1d-Cre;mT/mG mice show 
the presence of GFP (green fluorescent 
protein)+ collecting duct epithelial cells. 
Immunofluorescence for AQP2 (aquaporin 2) 
show colocalization with GFP+ collecting duct 
cells in both diabetic and nondiabetic Ren1d-
Cre;mT/mG mice. B, Colocalization analysis 
of GFP+ cells and immunofluorescence 
for AQP2 cells using Pearson correlation 
coefficient show no difference between 
kidneys of control and diabetic Ren1d-
Cre;mT/mG mice. C, A large image analysis 
of the GFP and AQP2 colocalized area per 
total area shows no significant difference 
between kidneys of control and diabetic 
Ren1d-Cre;mT/mG mice. STZ denotes 
streptozotocin-treated mice; n=5 in each 
group. ns indicates nonsignificant.
Figure 6. Renin colocalization with renin lineage cells (RLC) near the glomerular pole (A, arrows) and in tubules (B, arrowheads) in kidney sections from renin-
reporter mice. Green reflects RLC and tomato red labels the kidney structures. Renin protein staining (blue). The areas of colocalization in turquoise color 
of renin and renin lineage cells are near the glomerular pole (merged image in A, white arrows) and in few areas of tubular epithelium (merged image in B, 
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account for increased urinary renin production in streptozotocin-
treated mice, we developed a mouse line resulting from the cross 
of Ren1d-Cre mice with mT/mG reporter mice and used strep-
tozotocin to induce chronic diabetes mellitus.6 These mice, GFP 
labels cells (and all their descendants) permanently at the sites 
where Cre-recombination occurs, enabling tracing of cells of 
renin lineage, that is, those cells that either actively express renin 
or are derived from ureteric bud epithelial cells or Six 2 derived 
progenitors that expressed renin earlier during development.6
Consistent with previous studies,6 we found that in Ren1d-
Cre;mT/mG mice the GFP+ cells were present in the renal arte-
rial tree (including JGA cells), CD epithelial cells in the kidney 
cortex, medulla, and papilla. Immunostaining for aquaporin 
colocalized with GFP+ CD cells of Ren1d-Cre;mT/mG mice 
(Figure 5A). There were, however, no appreciable differences 
in colocalization pattern or intensity between renin-reporter 
mice with and without diabetes mellitus (Figure 5B). We also 
observed frequent expression of RLCs in the glomerular parietal 
epithelium and their occasional expression within the glomer-
ular tuft (Figure S4A). The level of expression of GFP positive 
cells within either of these glomerular locations was not sig-
nificantly different between control and streptozotocin-treated 
mice (Figure S4B). In the aggregate, therefore, data from the 
renin-reporter mice provides no evidence of migration of RLCs 
to the CD or intraglomerular locations in mice made diabetic by 
streptozotocin as compared to nondiabetic controls.
The lack of differences in the presence of RLCs at var-
ious nephron segments does not inform, however, whether 
the GFP+ cells at the time after diabetes mellitus induction 
actively produce renin or are dormant. We, therefore, evalu-
ated renin mRNA expression in microdissected kidney PT and 
CCD from control and streptozotocin-treated diabetic mice. 
No significant differences were noted in the levels of mouse 
renin mRNA in the PT or in the CCD (Table S3). This suggests 
that local renin production at those sites cannot contribute to 
the markedly increased urinary renin found in streptozotocin-
treated mice. In the CDs of streptozotocin-treated diabetic 
mice, by contrast, the renin immunostaining was increased as 
previously reported for prorenin.19 The possibility that part of 
the increased urinary renin that we find in diabetes mellitus 
could originate from conversion of prorenin in the collecting 
tubule cannot be ruled out in our studies. In our study, total 
renin enzyme immunoassay, that simultaneously detects both 
active renin and prorenin, yielded 10–100 higher values than 
the active renin enzyme immunoassay (Figure 1A and Figure 
S1). By simple subtraction of the results of 2 assays, one could 
assume that in the final urine the prorenin might predominate. 
Against this assumption, however, is the evidence presented by 
Roksnoer et al56 who demonstrated that the renin standard in-
cluded in the total renin enzyme immunoassay assay causes an 
upward shift resulting in artificially inflated total renin values. 
In addition, studies in humans and rats suggest that urinary 
renin reflects mostly active renin and not prorenin because al-
most no prorenin could be detected in the final urine.37,46
In the renal cortex, renin mRNA was significantly reduced 
in streptozotocin-treated mice as compared to controls (Table 
S3). Most of kidney cortex renin mRNA reflects JGA, the 
major physiological site for renin production.57 Consistent 
with this finding, renin staining in the JGA was reduced in 
streptozotocin-treated diabetic as compared to control mice 
(Figure 4). The finding of reduced JGA renin (by immunos-
taining) and reduced mRNA levels in the renal cortex, alto-
gether provides, by extrapolation to humans, an explanation 
for the low levels of PRA usually seen in patients with diabetic 
complications.26–30In fact, DKD is the most frequent cause 
of the syndrome of isolated hyporeninemic hypoaldosteron-
ism.58–61 In this syndrome, the reduced levels of PRA may be 
multifactorial but sclerosis of the JGA associated with tubule 
interstitial fibrosis has been occasionally documented.60 Our 
finding of reduced renin staining in the JGA of diabetic mice 
is, therefore, potentially relevant in explaining the known pre-
disposition to the syndrome of hyporeninemic hypoaldoste-
ronism, an important cause of hyperkalemia in patients with 
diabetes mellitus.58,59
Because we found no evidence for migration of RLC to the 
CD as the potential source of tubular renin, the increase in renin 
staining in CDs observed in this study by us and previously by 
others19 deserves an alternative explanation. In general, uri-
nary renin can originate from 3 different sources: from plasma 
renin that has been filtered and not completely reabsorbed by 
the proximal tubule, from renin that has been produced and 
released locally from kidney tubules, or from a conversion of 
plasma-derived prorenin to renin largely taking place distally 
in the CD where the PRR is abundant.39,41–43 Because of the rel-
atively small molecular size, renin is easily filterable and, of 
course, more in the presence of glomerular pathology due to 
DKD. Renin staining in the apical part of proximal tubule cells 
has long been believed to represent filtered and pinocytozed 
renin.62 The proximal tubule is the principal site of uptake of 
proteins, including renin, a process which appears to be mainly 
megalin-mediated.37,53 The observed decrease in proximal tu-
bular renin staining (Figure 4C) suggests that increased urinary 
renin could be a result of diminished capacity of the proximal 
tubule to reabsorb renin. Of note, we found in diabetic strepto-
zotocin-treated mice that kidney mRNA expression of megalin, 
an endocytosis receptor, was decreased (Figure S3A) which is 
in agreement with previous reports in streptozotocin-treated 
rats63,64 and Ove-26 mice.65 It has been shown that decreased 
kidney megalin expression in diabetic rats was associated with 
reduced reabsorption of albumin63 and increased loss of other 
urinary proteins, such a transferrin.64 Megalin’s major role in 
proximal tubule renin reabsorption is suggested by studies 
using megalin knockout53 We, therefore, surmise that the in-
crease in urinary renin excretion in diabetic mice is due to a 
reduced kidney expression of megalin causing reduced prox-
imal tubular reabsorption of renin. The lack of differences in 
renin mRNA between control and diabetic mice at the CCD, 
noted above, further shows that the source of urinary renin in 
DKD cannot be due to local production at this tubular site.
Our findings in the streptozotocin-model of diabetes mel-
litus are in full agreement with recent work by Roksnoer et al37 
who have emphasized that normally renin appears in the urine 
as a result of filtration and only in small amounts because prox-
imal reabsorption retains the majority of the filtered renin. In a 
series of elegant experiments using urine samples from patients 
with Dent disease and Lowe syndrome, entities with impaired 
proximal tubular reabsorption of low molecular weight proteins, 
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importance of intact tubular processing.37 In our studies, urinary 
albumin was increased in diabetic as compared to control mice 
likely as the result of increased filtration due to a disturbed filtra-
tion barrier in diabetic mice. Likewise, this glomerular alteration 
can explain increased renin in the urine even if renin secretion 
from the JGA is reduced. Although this undoubtedly contrib-
utes to high urinary renin, the finding of reduced expression of 
megalin in the kidney cortex in diabetic as compared to con-
trol mice suggests a likely role of impaired tubular reabsorption 
as a contributor to high urinary levels of renin in diabetic mice. 
Our approach to further demonstrate the importance of prox-
imal tubular reabsorption of renin in diabetic mice was based 
on infusing renin with and without lysine, a blocker of prox-
imal tubular reabsorption. Tubular reabsorption of peptides and 
proteins can be inhibited by coadministration of cationic amino 
acids, such as l-lysine or l-arginine.66,67 Megalin binds proteins 
rich in positively charged amino acids and cationic compounds. 
It is believed that l-lysine saturate those binding sites and, there-
fore, interfere with renal reabsorption of proteins. Intravenously 
infused l-lysine has been previously used to inhibit tubular up-
take of renin causing greatly increased urinary renin excretion.66 
Consistent with previous reports,66,68 we found that L-lysine 
caused marked increases in urinary excretion of endogenous and 
exogenous mouse renin. While at baseline, urinary mouse renin 
was noticeably higher in diabetic than in control mice, after 
L-lysine injection, the markedly increased urinary mouse renin 
levels were no longer significantly different statistically between 
control and diabetic streptozotocin-treated mice (Figure 3A). 
Because endogenous mouse renin can originate from plasma or 
the kidney, we injected intravenous human active renin protein to 
trace the fate of only plasma renin that has been filtered. For this, 
human renin protein was infused and detected using an assay 
which identifies only human active renin and no mouse renin. 
Injection of human renin alone resulted in a detection of low 
levels of human active renin in the urine of control mice and a 
much accentuated urinary levels in diabetic mice. Similar to en-
dogenous mouse renin, coadministration of l-lysine with human 
renin resulted in marked augmentation in urinary levels of active 
human renin in both diabetic and nondiabetic mice, such that 
urinary renin was no longer significantly different (Figure 3B). 
The findings of similar levels of both mouse (Figure 3A) and 
human renin (Figure 3B) when proximal tubular reabsorption 
is blocked by lysine shows that increased urinary renin in dia-
betes mellitus is largely due to impaired proximal tubular reab-
sorption. It should be noted, however, that l-lysine can increase 
the GFR, which might contribute to increased levels of renin in 
the urine.69,70 Decreased expression or saturation of megalin re-
ceptor in diabetic PT likely underlies this process. This is fur-
ther supported by a recent study, reporting a marked increase 
in urinary renin when the megalin receptor is antagonized.54 In 
DKD, therefore, the source of urinary renin is increased filtered 
renin, through an abnormal glomerular barrier, which cannot ef-
ficiently be reabsorbed by the proximal tubule.
In conclusion, in humans with type 1 diabetes mellitus 
and DKD, as well as in mice with streptozotocin-induced di-
abetes mellitus, urinary renin is increased. Our data show that 
impaired proximal tubular reabsorption of filtered renin con-
tributes to the increase of urinary renin in DKD likely due 
to decreased expression of megalin receptor. Studies in the 
renin-reporter mice made diabetic by streptozotocin, more-
over, provide no evidence for migration of cells of the renin 
lineage to CDs that could be responsible for renin secretion 
and thus increased urinary renin in diabetes mellitus.
Perspectives
Renin is the key enzyme within the RAS that generates Ang I 
by hydrolyzing its unique substrate, angiotensinogen. As such, 
activation of the RAS is essentially dependent on circulating 
levels of renin produced by the JGA. It has been suggested, 
however, that the kidney CDs may also contribute to renin for-
mation. In patients with DKD, PRA is usually decreased, but 
there is limited information on urinary renin and its origin. In 
the present study, we studied urinary renin from patients with 
type 1 diabetes mellitus and DKD and from mice with strep-
tozotocin-induced diabetes mellitus and showed that urinary 
renin is elevated. By immunohistochemistry studies in mice 
with streptozotocin-induced diabetes mellitus, it was found that 
renin staining was reduced in the JGA but increased in the CDs. 
Using a renin-reporter mouse model made diabetic by strepto-
zotocin administration, it is shown that this increase in urinary 
renin cannot be attributed to production from cells of the renin 
lineage migrating to the CD in a chronic hyperglycemic envi-
ronment. The findings obtained by infusing l-lysine to block 
proximal tubular reabsorption moreover suggest that much of 
the urinary renin originates from filtered renin that cannot be 
reclaimed by the proximal tubule. Reduced megalin expression 
in the setting of DKD may account for reduced proximal reab-
sorption and therefore increase urinary renin. Future studies in 
patients with DKD should examine if renin staining in the JGA 
is decreased as demonstrated here in diabetic mice.
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What Is New?
•	Urinary renin is increased in a cohort of patients with type 1 diabetes 
mellitus and chronic kidney disease.
•	Distribution of renin lineage cells was investigated for the first time in a 
renin-reporter mouse model made diabetic.
What Is Relevant?
•	This study provides insight on the origin of urinary renin and its relevance 
in the setting of diabetic kidney disease.
•	This is important because the activation of the renin-angiotensin system 
within the kidney causes sodium retention, hypertension, and progres-
sion of chronic kidney disease.
Summary
In humans with diabetic kidney disease and mice with diabetes 
mellitus induced by streptozotocin, urinary renin is increased. The 
source of this increase is largely attributable to increased filtration 
and impaired proximal tubular reabsorption. Filtered renin rather 
than local production of renin from migration of cells of the renin 
lineage to the renal collecting ducts in a hyperglycemic environ-
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